NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson reported six Form 4 transactions involving performance rights linked to ordinary shares. All are coded as “other acquisition or disposition” (code J) and classified as restructuring transactions covering an aggregate 2,932,881 performance rights at an exercise price of $0.0000 per right. No shares were reported as bought or sold, and the transaction summary shows zero net buy or sell activity.
NOVONIX LIMITED reported that 2,932,881 unquoted NVXAD performance rights have lapsed because the performance conditions were not met or can no longer be satisfied. No consideration was paid for this cessation.
After this change, the company has 862,227,757 ordinary fully paid shares on issue, alongside remaining unquoted performance rights, options, share rights and convertible notes.
NOVONIX Limited has applied to quote 784,817 new ordinary fully paid shares on the ASX, issued on 13 May 2026 after the conversion of performance rights under an employee incentive scheme. These additional shares form part of the existing NVX ordinary share class and rank equally with existing shares.
The shares are being issued for non‑cash consideration, with an estimated value of AUD 0.235 per security. After this quotation, the company reports a total of 862,227,757 NVX ordinary fully paid shares on issue, alongside several classes of unquoted performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
Novonix Limited filed a Form 6-K providing several ASX Appendix 3Y notices that record changes in directors’ interests. The changes mainly reflect the issue of 195,938 share rights to multiple directors following shareholder approval at the AGM on 15 April 2026. For example, Ron Edmonds now holds 416,342 ordinary shares and 195,938 share rights, while Sharan Burrow holds 215,739 ordinary shares and 195,938 share rights. These changes are described as issues of share rights rather than trades during a closed period.
NOVONIX LIMITED has issued 1,371,566 new unquoted Share Rights as a separate security class. These rights were not issued for cash consideration and will rank equally in all respects from their issue date of 6 May 2026.
The Share Rights form a new, unquoted ASX security class and increase NOVONIX’s unquoted securities alongside existing performance rights, options, convertible notes and convertible debentures. The issue is being put to security holders for approval under ASX Listing Rule 7.1 at a meeting dated 15 April 2026.